Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Odomzo: locally advanced Basal Cell Carcinoma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Broader topic: Basal Cell Carcinoma

Source population
Not part of this definition
Disease extent
locally-advanced
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      following surgery or radiation therapy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Odomzo (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

    Study evidence for this setting

    4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00492089 · Registry condition search · Scope: unclear

    Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

    1 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT00833417 · Source cited / selected · Scope: unclear

    A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

    6 outcome links · 1 safety-group records · 1 quality-of-life measures

    →

    NCT01327053 · Source cited / selected · Scope: unclear

    A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT02123511 · Registry condition search · Scope: unclear

    Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

    6 outcome links · 2 safety-group records · 3 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice